Cash from Operations (Quarterly) Chart

View Cash from Operations (Quarterly) for GOSS.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (Quarterly) Chart
Start Trial

Historical Cash from Operations (Quarterly) Data

View and export this data back to 2017. Start Trial.
Date Value
June 30, 2026 -41.39M
March 31, 2026 -38.72M
December 31, 2025 -48.31M
September 30, 2025 -36.17M
June 30, 2025 -47.06M
March 31, 2025 -39.72M
December 31, 2024 -35.48M
September 30, 2024 -32.03M
June 30, 2024 116.35M
March 31, 2024 -52.30M
December 31, 2023 -33.42M
September 30, 2023 -34.49M
June 30, 2023 -38.25M
March 31, 2023 -52.99M
December 31, 2022 -47.73M
September 30, 2022 -37.00M
June 30, 2022 -48.82M
March 31, 2022 -53.48M
Date Value
December 31, 2021 -40.51M
September 30, 2021 -42.04M
June 30, 2021 -47.45M
March 31, 2021 -58.90M
December 31, 2020 -36.74M
September 30, 2020 -44.93M
June 30, 2020 -42.40M
March 31, 2020 -52.30M
December 31, 2019 -44.14M
September 30, 2019 -36.11M
June 30, 2019 -36.81M
March 31, 2019 -27.77M
December 31, 2018 -25.02M
September 30, 2018
June 30, 2018
March 31, 2018 -3.708M
December 31, 2017 -5.721M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Quarterly) Range, Past 5 Years

View Cash from Operations (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Quarterly) Benchmarks

View Cash from Operations (Quarterly) Benchmarks
Start Trial
United Therapeutics Corp. 310.20M
Arbutus Biopharma Corp. -5.952M
Kura Oncology, Inc. -62.55M
ACADIA Pharmaceuticals, Inc. 100.78M
Alnylam Pharmaceuticals, Inc. 326.72M